

Cover Story
NCI
By Matthew Bin Han Ong
The pace of innovation in oncology has made U.S. cancer researchers prime targets for foreign state-sponsored programs aimed at diverting intellectual property.
By Matthew Bin Han Ong
In Brief


Funding Opportunities
Clinical Roundup


Drugs & Targets


Trending Stories
- Lawsuits brought against Tempus AI raise more questions than answers about DNA privacy in the AI era
- Two lawsuits vs. Tempus raise questions about privacy of germline data in cancer RWE
“Deidentified” ≠ “deidentifiable” - Mt. Sinai forms committee to probe Epstein links to breast center founder Eva Dubin, other faculty members
- Mail-out colorectal cancer screening programs extend, rather than replace, clinical care
- Trump administration announces “major crackdown” on healthcare fraud
- Lou Weiner to step down as director of Georgetown’s Lombardi CCC after 18 years














